OCSI - Oscient says Q3 revenue to be more than $11 million Oct 11 (Reuters) - Biopharmaceutical firm Oscient Pharmaceuticals Corp. (OSCI.O: Quote, Profile, Research) said on Wednesday it expects total third-quarter revenues of slightly more than $11 million.
In a statement, the company said it expects the total cash, restricted cash and investments balance as of the quarter ended September 30 to be about $51 million. (Reporting by Swagata Gupta in Bangalore)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.